Analyst Ratings For Bioventix PLC (LON:BVXP)
Today, FinnCap reiterated its Corporate rating on Bioventix PLC (LON:BVXP) with a price target of GBX 1,450.
There are no ratings tracked in the last 12 months. on the stock.
The current consensus rating on Bioventix PLC (LON:BVXP) is N/A (Score: NaN) with a consensus target price of GBX 1,450 per share, a potential .
Some recent analyst ratings include
- 2/24/2017-FinnCap Reiterated Rating of Corporate.
About Bioventix PLC (LON:BVXP)
Bioventix PLC is a United Kingdom-based biotechnology company. The principal activity of the Company is the development and supply of antibodies. The Company specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. The Company’s non-vitamin D business consists of antibodies, NT proBNP (heart failure), testosterone, Free Triiodothyronine (FT3) (thyroid hormone), estradiol, and various drugs, such as tetrahydrocannabinol (THC)/cannabis, and progesterone. The Company offers products for indications, such as thyroid, fertility, oncology, cardiac, vitamin D, drug of abuse, infectious disease and miscellaneous. Its sheep hybridoma technology produces cell lines that secrete SMAs. The Company offers a panel of SMAs to 25-OH D and has various 25-OH D2 and 25-OH D3 specific antibodies. It sells its products through direct sales and through distributors.
Recent Trading Activity for Bioventix PLC (LON:BVXP)
Shares of Bioventix PLC closed the previous trading session at 1,572.50 up +22.50 1.45% with 0 shares trading hands.